CJC-1295 (No DAC) / Hexarelin Blend
Also known as: CJC-1295 & Hexarelin, Mod GRF 1-29 & Hexarelin, Spartan 1
This blend combines CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with Hexarelin, one of the most potent ghrelin-mimetic secretagogues, to drive a strong synergistic growth hormone pulse. Both are unapproved research peptides.
Last updated
Mechanism of Action
CJC-1295 without DAC is a modified GHRH(1-29) analog that binds the pituitary GHRH receptor and increases the amplitude of natural growth-hormone pulses. Hexarelin is a synthetic hexapeptide GHS-R1a agonist that is among the most potent GHRPs for triggering GH release and suppressing somatostatin tone, and it also shows cardioprotective activity through the CD36 receptor. Combining a GHRH analog with Hexarelin produces a strong synergistic GH response via complementary receptor pathways. The short half-life of the no-DAC form preserves pulsatile GH and IGF-1 release; with prolonged Hexarelin exposure, GHS-R1a desensitization can attenuate the response over time.
- Half-life
- Short for both components: roughly 30 minutes for CJC-1295 no DAC and about 55-70 minutes for Hexarelin
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Potent synergistic growth hormone release
- Raises downstream IGF-1 in research models
- Hexarelin shows additional cardioprotective activity in studies
- Studied for lean mass, strength, and recovery endpoints
- Short-acting profile preserves physiologic GH pulses
- Combines two complementary GH-release pathways
Potential Side Effects
- Injection-site redness or irritation
- Water retention, tingling, or numbness
- Elevated cortisol or prolactin
- Possible receptor desensitization with prolonged use
- Headache, flushing, or reactive hypoglycemia
Common Dosing
For research use only and not medical advice: research protocols commonly combine roughly 100 mcg CJC-1295 (no DAC) with 100 mcg Hexarelin per subcutaneous administration, often dosed 1-2 times daily on an empty stomach, with limited continuous duration to reduce desensitization. No validated human dosing exists.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active or history of malignancy (GH and IGF-1 elevation)
- Uncontrolled diabetes or significant insulin resistance
- Pregnancy or breastfeeding
CJC-1295 (No DAC) / GHRP-2 Blend
This blend pairs CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with GHRP-2, a growth hormone secretagogue, to synergistically stimulate pulsatile growth hormone release. Both are unapproved research peptides.
Hexarelin
A potent growth hormone releasing peptide and ghrelin receptor agonist, among the strongest GH-stimulating GHRPs, with additional cardioprotective effects studied in preclinical work.
CJC-1295
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
Ipamorelin
A selective ghrelin receptor agonist (growth hormone secretagogue) prized for stimulating GH release with minimal effect on cortisol or prolactin. Considered one of the gentler GH peptides.
- View
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006
- View
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man
1994
- View
Hypothalamic control of growth hormone (GH) secretion in type I diabetic men: effect of the combined administration of GH-releasing hormone and hexarelin, a novel GHRP-6 analog
1996
- View
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
2006
- View
The cardiovascular action of hexarelin
2014